Display options
Cite
Pünchera J, Barnes L, Kaya G. Lrig1 Expression in Human Sebaceous Gland Tumors. Dermatopathology (Basel). 2016;3(2):44-54doi: 10.1159/000446427.
Pünchera, J., Barnes, L., & Kaya, G. (2016). Lrig1 Expression in Human Sebaceous Gland Tumors. Dermatopathology (Basel, Switzerland), 3(2), 44-54. https://doi.org/10.1159/000446427
Pünchera, Jöri, et al. "Lrig1 Expression in Human Sebaceous Gland Tumors." Dermatopathology (Basel, Switzerland) vol. 3,2 (2016): 44-54. doi: https://doi.org/10.1159/000446427
Pünchera J, Barnes L, Kaya G. Lrig1 Expression in Human Sebaceous Gland Tumors. Dermatopathology (Basel). 2016 Jun 01;3(2):44-54. doi: 10.1159/000446427. eCollection 2016. PMID: 27504445; PMCID: PMC4965540.
Copy Download .nbib Format: NLM
Share it on

Dermatopathology (Basel). 2016 Jun 01;3(2):44-54. doi: 10.1159/000446427. eCollection 2016.

Lrig1 Expression in Human Sebaceous Gland Tumors.

Dermatopathology (Basel, Switzerland)

Jöri Pünchera, Laurent Barnes, Gürkan Kaya

Affiliations

  1. Department of Dermatology, University Hospital of Geneva, Geneva, Switzerland.

PMID: 27504445 PMCID: PMC4965540 DOI: 10.1159/000446427

Abstract

BACKGROUND: Sebaceous glands contribute significantly to the barrier functions of the skin. However, little is known about their homeostasis and tumorigenesis. Recently, increased expression of stem cell marker Lrig1 has been reported in sebaceous carcinoma-like tumors of K14ΔNLef1 transgenic mice. In this study, we analyzed the Lrig1 expression in human sebaceous tumors.

METHODS: Twenty-eight formalin-fixed paraffin-embedded sebaceous tumor specimens (7 sebaceous hyperplasias, 7 sebaceous adenomas, 10 sebaceomas and 4 sebaceous carcinomas) were stained with anti-Lrig1, anti-CD44v3 and anti-Ki67 antibody.

RESULTS: Four (100%) sebaceous carcinomas, 8 (80%) sebaceomas, 3 (43%) sebaceous adenomas and no sebaceous hyperplasia showed Lrig1 overexpression.

DISCUSSION AND CONCLUSION: Lrig1 is a known tumor suppressor gene and is usually considered to be an indicator of poorly aggressive tumors. In human sebaceous tumors, the stronger Lrig1 staining in sebaceous carcinoma compared to other sebaceous tumors might be a feature of an advanced stage in tumorigenesis and a bad prognosis. In our study, 100% of sebaceous carcinomas revealed Lrig1 overexpression. We propose that Lrig1 may be used as a possible new marker of poorly differentiated sebaceous carcinoma.

Keywords: CD44; Lrig1; Sebaceous adenoma; Sebaceous carcinoma; Sebaceous gland; Sebaceous tumor; Stem cells

References

  1. J Invest Dermatol. 1999 Oct;113(4):523-32 - PubMed
  2. Nat Genet. 1999 Nov;23(3):268-70 - PubMed
  3. J Invest Dermatol. 1999 Dec;113(6):1006-10 - PubMed
  4. EMBO J. 2001 Mar 15;20(6):1215-22 - PubMed
  5. J Nutr. 2001 Sep;131(9):2260-8 - PubMed
  6. J Invest Dermatol. 2002 Feb;118(2):216-25 - PubMed
  7. FEBS Lett. 2002 Jun 19;521(1-3):67-71 - PubMed
  8. J Invest Dermatol. 2003 May;120(5):728-37 - PubMed
  9. Am J Surg Pathol. 2004 Feb;28(2):168-77 - PubMed
  10. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6 - PubMed
  11. J Biol Chem. 2004 Nov 5;279(45):47050-6 - PubMed
  12. Dermatol Surg. 2005 Apr;31(4):423-30 - PubMed
  13. Infect Immun. 2005 Aug;73(8):4512-21 - PubMed
  14. Curr Biol. 2005 Aug 9;15(15):1340-51 - PubMed
  15. Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11958-63 - PubMed
  16. Nature. 2007 Mar 8;446(7132):185-9 - PubMed
  17. Biol Chem. 2007 Apr;388(4):405-18 - PubMed
  18. J Lipid Res. 2008 Jan;49(1):4-11 - PubMed
  19. Int J Cosmet Sci. 2004 Dec;26(6):291-311 - PubMed
  20. Cell Stem Cell. 2008 Jul 3;3(1):33-43 - PubMed
  21. J Lipid Res. 2009 Apr;50 Suppl:S417-22 - PubMed
  22. Dermatol Ther. 2008 Nov-Dec;21(6):459-66 - PubMed
  23. Nat Rev Mol Cell Biol. 2009 Mar;10(3):207-17 - PubMed
  24. Cell Stem Cell. 2009 May 8;4(5):427-39 - PubMed
  25. Science. 2010 Mar 12;327(5971):1385-9 - PubMed
  26. Mol Cancer Res. 2011 Oct;9(10):1406-17 - PubMed
  27. Antimicrob Agents Chemother. 2012 Mar;56(3):1157-61 - PubMed
  28. Dev Biol. 2012 Mar 1;363(1):138-46 - PubMed
  29. Cell. 2012 Mar 30;149(1):146-58 - PubMed
  30. Skin Pharmacol Physiol. 2012;25(4):167-81 - PubMed
  31. Semin Cell Dev Biol. 2012 Oct;23(8):928-36 - PubMed
  32. Cell Rep. 2013 Feb 21;3(2):427-41 - PubMed
  33. Cell Stem Cell. 2013 Oct 3;13(4):471-82 - PubMed
  34. Biochim Biophys Acta. 2014 Mar;1841(3):319-22 - PubMed
  35. J Eur Acad Dermatol Venereol. 2014 May;28(5):527-32 - PubMed
  36. J Clin Invest. 2014 Jan;124(1):385-97 - PubMed
  37. Cancer Res. 2014 Jun 1;74(11):2928-35 - PubMed
  38. Mol Cell Biol. 2014 Aug;34(16):3086-95 - PubMed
  39. Int J Clin Exp Pathol. 2014 Jun 15;7(7):3632-46 - PubMed
  40. Acta Oncol. 2014 Sep;53(9):1135-42 - PubMed
  41. Biomed Pharmacother. 2014 Jul;68(6):693-7 - PubMed
  42. Arch Pathol Lab Med. 2014 Dec;138(12):1685-9 - PubMed
  43. Oncogene. 2015 Oct;34(43):5505-12 - PubMed
  44. Invest Ophthalmol Vis Sci. 2015 Feb 24;56(3):1813-9 - PubMed
  45. Acta Oncol. 2015;54(8):1113-9 - PubMed
  46. Cell Stem Cell. 2015 Apr 2;16(4):400-12 - PubMed
  47. Dermatology. 2015;231(2):116-8 - PubMed
  48. Front Oncol. 2015 Aug 10;5:180 - PubMed
  49. Physiol Rev. 1989 Apr;69(2):383-416 - PubMed
  50. Mol Carcinog. 2016 Dec;55(12):1962-1973 - PubMed
  51. Medicine (Baltimore). 2015 Nov;94(47):e2081 - PubMed
  52. PLoS One. 2017 Jan 18;12(1):e0169452 - PubMed
  53. Am J Dermatopathol. 1984 Feb;6(1):7-13 - PubMed
  54. Arch Ophthalmol. 1998 Feb;116(2):195-8 - PubMed

Publication Types